Physician profile
Charles Craft
NPI 1013945138
$6,302.72
in general payments reported to CMS, 2019-2025
35 companies · $21.09 in 2025
The $21.09 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $937 · 2020: $2,362 · 2021: $2,192 · 2022: $640 · 2023: $59.42 · 2024: $91.30 · 2025: $21.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $171.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $786.71 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $710.12 | 2019-2022 | |
| Glaxosmithkline, LLC. | $684.91 | 2019-2022 | |
| Amgen INC. | $493.78 | 2019-2022 | |
| Abbvie INC. | $455.65 | 2020-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $446.36 | 2019-2021 | |
| Novo Nordisk INC | $368.12 | 2019-2022 | |
| Abbott Laboratories | $300.97 | 2021-2025 | Freestyle Libre, Freestyle Libre 3 |
| Pfizer INC. | $289.45 | 2019-2022 | |
| Allergan, INC. | $273.56 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $201.11 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $173.32 | 2021 | |
| Lilly USA, LLC | $130.49 | 2021-2022 | |
| Upsher-Smith Laboratories LLC | $100.63 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $95.81 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $90.80 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $86.51 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $86.16 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $82.71 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.02 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $64.36 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $54.62 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $31.71 | 2020 | |
| Sanofi Pasteur INC. | $30.05 | 2021 | |
| Alexion Pharmaceuticals, INC. | $27.31 | 2020 | |
| Merck Sharp & Dohme LLC | $26.70 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $24.74 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $19.14 | 2022 | |
| Alfasigma USA, INC. | $18.11 | 2021 | |
| Genentech USA, INC. | $13.59 | 2020 | |
| Jazz Pharmaceuticals INC. | $13.30 | 2021 | |
| Eisai INC. | $12.58 | 2020 | |
| Astellas Pharma US INC | $11.65 | 2021 | |
| Mylan Specialty L.P. | $11.44 | 2020 | |
| Sanofi-Aventis U.S. LLC | $11.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Craft listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.